For decades, pharmaceutical manufacturing has been rapidly moving overseas. With over 80% of active pharmaceutical ingredients and 40% of finished medications now imported, America’s drug supply chain has become increasingly vulnerable. It’s no secret that pharmaceutical outsourcing has led to quality control issues. In 2018, contaminated API from China caused a recall of millions of blood pressure medications. Overseas facilities simply don’t face the same FDA scrutiny as U.S. plants. As more and more manufacturing has moved offshore, America’s access to safe, high-quality medicines has suffered.
However, one company is trying to bring vital medicine production back to the United States. Medivant Healthcare, founded in 2015 in Phoenix, Arizona, exemplifies the U.S. pharmaceutical landscape. The company operates two fully automated facilities in Chandler, Arizona, specializing in sterile injectable medications. These facilities are not just production sites but hubs of quality and precision. Adherence to cGMP (Current Good Manufacturing Practice) standards and FDA guidelines is not just regulatory compliance for Medivant but a foundational principle.
Medivant’s Chandler facility combines state-of-the-art technology with meticulous process control to produce 40,000 single-dose liquid injectable vials daily. This output level is significant in addressing the ongoing challenge of medication shortages in the U.S. Each vial produced is a testament to Medivant’s commitment to quality, embodying its dedication to enhancing patient care and filling critical gaps in the U.S. healthcare system.
Quality assurance at Medivant is a multi-layered process underpinned by a team of experienced professionals. The Quality Unit employs advanced testing methodologies, ensuring each product batch meets rigorous standards. This commitment to quality transcends typical business objectives, reflecting Medivant’s dedication to patient safety and well-being. The company’s proactive approach to quality assurance and compliance positions it as a reliable partner in the healthcare sector.
In addition, innovation is a cornerstone of the American pharmaceutical sector, and U.S.-based manufacturing taps into this dynamic environment. The U.S. is home to some of the world’s leading research institutions and a skilled workforce, fostering a culture of continuous improvement and technological advancement in pharmaceutical manufacturing. This culture of innovation is evident in Medivant’s approach to production, where the latest technologies and processes are employed to enhance the efficiency, effectiveness, and safety of medications.
Medivant’s team, comprising over 100 professionals, is integral to its operations. These individuals are not just manufacturing experts; they are well-versed in the regulatory aspects of pharmaceutical production. Their expertise ensures that every batch of medication produced is safe and compliant with national and international standards. This team’s dedication is a cornerstone of Medivant’s ability to provide reliable healthcare solutions.
The impact of Medivant’s U.S.-based operations extends beyond the pharmaceutical industry. Each medication produced directly affects individuals’ lives, embodying the company’s larger mission to improve healthcare outcomes. The choice to manufacture in the United States underscores Medivant’s commitment to quality and efficiency and the broader goal of enhancing the American healthcare landscape.
A relentless pursuit of excellence and innovation characterizes Medivant Healthcare’s journey. The company’s advanced facilities, commitment to quality, and proactive approach solidifies its position as a leader in U.S.-based pharmaceutical manufacturing. As Medivant continues to grow and evolve, it remains focused on its core mission: to ensure the health and well-being of communities through reliable, high-quality pharmaceutical products. In doing so, Medivant is not just a manufacturer but a vital contributor to public health, leading the way in a rapidly changing healthcare landscape.
